Publikationen im NUM
Hier finden Sie eine Liste der Publikationen, die im Zusammenhang mit dem Netzwerk Universitätsmedizin in der ersten und zweiten Förderphase entstanden sind.
A. Deckert,
M. De Allegri and
et al,
"Effectiveness and cost-effectiveness of four different strategies for SARS-CoV-2 surveillance in the general population (CoV-Surv Study): study protocol for a two-factorial randomized controlled multi-arm trial with cluster sampling",
Trials,
vol. 22,
no. 1,
2021.
| DOI: | 10.1186/s13063-021-05619-5 |
P. Beschoner,
M. Jarczok,
M. Kempf,
K. Weimer,
F. Geiser,
N. Hiebel,
Y. Erim,
E. Morawa,
S. Steudte-Schmiedgen and
L. Jerg-Bretzke,
"egePan-VOICE study on the psychosocial burden of the Covid-19 pandemic among medical technical assistants",
Z Psychosom Med Psychother,
2021.
S. Zellmer,
M. Kahn,
A. Ebigbo and
et al,
"Ein Jahr Covid-19: Testung, Verwendung von Schutzausrüstung und Auswirkungen auf die Gastrointestinale Endoskopie in Deutschland",
Z Gastroenterol,
vol. 59,
no. 8,
2021.
| DOI: | 10.1055/s-0041-1734140 |
M. Kahn,
S. Zellmer,
A. Ebigbo and
et al,
"Ein Jahr Covid-19: Testung, Verwendung von Schutzausrüstung und Auswirkungen auf die Gastrointestinale Endoskopie in Deutschland",
Z Gastroenterol,
vol. 59,
no. 12,
2021.
| DOI: | 10.1055/a-1649-8184 |
B. Jensen,
N. Luebke,
T. Feldt,
V. Keitel,
T. Brandenburger,
D. Kindgen-Milles,
M. Lutterbeck,
N. F. Freise,
D. Schoeler,
R. Haas,
A. Dilthey,
A. Walker,
J. Timm and
T. Luedde,
"Emergence of the E484K mutation in SARS-COV-2-infected immunocompromised patients treated with bamlanivimab in Germany",
The Lancet regional health. Europe,
vol. 8,
pp. 100164,
2021.
Abstract:
BACKGROUND Monoclonal antibodies (mAb) have been introduced as a promising new therapeutic approach against SARS-CoV-2. At present, there is little experience regarding their clinical effects in patient populations underrepresented in clinical trials, e.g. immunocompromised patients. Additionally, it is not well known to what extent SARS-CoV-2 treatment with monoclonal antibodies could trigger the selection of immune escape viral variants. METHODS After identifying immunocompromised patients with viral rebound under treatment with bamlanivimab, we characterized the SARS-CoV-2-isolates by whole genome sequencing. Viral load measurements and sequence analysis were performed consecutively before and after bamlanivimab administration. FINDINGS After initial decrease of viral load, viral clearance was not achieved in five of six immunocompromised patients treated with bamlanivimab. Instead, viral replication increased again over the course of the following one to two weeks. In these five patients, the E484K substitution - known to confer immune escape - was detected at the time of viral rebound but not before bamlanivimab treatment. INTERPRETATION Treatment of SARS-CoV-2 with bamlanivimab in immunocompromised patients results in the rapid development of immune escape variants in a significant proportion of cases. Given that the E484K mutation can hamper natural immunity, the effectiveness of vaccination as well as antibody-based therapies, these findings may have important implications not only for individual treatment decisions but may also pose a risk to general prevention and treatment strategies. FUNDING All authors are employed and all expenses covered by governmental, federal state, or other publicly funded institutions.
| DOI: | 10.1016/j.lanepe.2021.100164 |
Abstract:
BACKGROUND Monoclonal antibodies (mAb) have been introduced as a promising new therapeutic approach against SARS-CoV-2. At present, there is little experience regarding their clinical effects in patient populations underrepresented in clinical trials, e.g. immunocompromised patients. Additionally, it is not well known to what extent SARS-CoV-2 treatment with monoclonal antibodies could trigger the selection of immune escape viral variants. METHODS After identifying immunocompromised patients with viral rebound under treatment with bamlanivimab, we characterized the SARS-CoV-2-isolates by whole genome sequencing. Viral load measurements and sequence analysis were performed consecutively before and after bamlanivimab administration. FINDINGS After initial decrease of viral load, viral clearance was not achieved in five of six immunocompromised patients treated with bamlanivimab. Instead, viral replication increased again over the course of the following one to two weeks. In these five patients, the E484K substitution - known to confer immune escape - was detected at the time of viral rebound but not before bamlanivimab treatment. INTERPRETATION Treatment of SARS-CoV-2 with bamlanivimab in immunocompromised patients results in the rapid development of immune escape variants in a significant proportion of cases. Given that the E484K mutation can hamper natural immunity, the effectiveness of vaccination as well as antibody-based therapies, these findings may have important implications not only for individual treatment decisions but may also pose a risk to general prevention and treatment strategies. FUNDING All authors are employed and all expenses covered by governmental, federal state, or other publicly funded institutions.
B. Jensen,
N. Luebke,
T. Feldt and
et al,
"Emergence of the E484K mutation in SARS-COV-2-infected immunocompromised patients treated with bamlanivimab in Germany",
Lancet Reg Health Eur,
vol. 8,
2021.
| DOI: | 10.1016/j.lanepe.2021.100164 |
L. Ruhl and
et al,
"Endothelial dysfunction contributes to severe COVID-19 in combination with dysregulated lymphocyte responses and cytokine networks",
Signal transduction and targeted therapy,
vol. 6,
pp. 418,
2021.
| DOI: | 10.1038/s41392-021-00819-6 |
[German]
S. Stillfried,
P. Boor and
D. PANDEMIcs,
"Entwicklung eines kooperativen Obduktionsnetzwerks aus Pathologie, Neuropathologie und Rechtsmedizin",
Pathologe,
pp. 1-5,
2021.
| DOI: | 10.1007/s00292-021-01004-w |
F. Zack,
S. Nigbur,
J. Manhart,
H. Derani,
D. Boy,
V. Kolbe and
A. Büttner,
"Erste Ergebnisse der Obduktionen der im Zusammenhang mit den SARS-CoV-2-Infektionen Verstorbenen aus der Unimedizin Rostock",
Ärztebl Meckl-Vorpom,
vol. 31,
pp. 125-128,
2021.
A. Revet,
J. Hebebrand,
L. Kehoe,
C. Child,
S. Bender and
P. Klauser,
"ESCAP CovCAP survey of heads of academic departments to assess the perceived initial (April/May 2020) impact of the COVID-19 pandemic on child and adolescent psychiatry services",
European Child & Adolescent Psychiatry,
2021.
| DOI: | 10.1007/s00787-020-01699-x |
R. Wagner,
D. Peterhoff,
S. Beileke and
et al,
"Estimates and determinants of SARS-Cov-2 seroprevalence and infection fatality ratio using latent class analysis: The population-based Tirschenreuth study in the hardest-hit German county in spring 2020",
Viruses,
vol. 13,
no. 6,
2021.
| DOI: | 10.3390/v13061118 |
| Datei: | https://doi.org/10.3390/v13061118 |
T. C. Jones and
et al,
"Estimating infectiousness throughout SARS-CoV-2 infection course",
Science (New York, N.Y.),
2021.
| DOI: | 10.1126/science.abi5273 |
K. A. Eberhardt and
et al,
"Evaluation of a New Spike (S)-Protein-Based Commercial Immunoassay for the Detection of Anti-SARS-CoV-2 IgG",
Microorganisms,
vol. 9,
2021.
| DOI: | 10.3390/microorganisms9040733 |
M. Korenkov,
N. Poopalasingam,
M. Madler and
et al,
"Evaluation of a Rapid Antigen Test To Detect SARS-CoV-2 Infection and Identify Potentially Infectious Individuals",
J Clin Microbiol,
vol. 59,
no. 9,
2021.
| DOI: | 10.1128/JCM.00896-21 |
T. Toptana,
L. Eckermann,
A. E. Pfeiffer and
et al,
"Evaluation of a SARS-CoV-2 rapid antigen test: Potential to help reduce community spread?",
J Clin Virol,
vol. 135,
2021.
| DOI: | 10.1016/j.jcv.2020.104713 |
M. Metzendorf and
R. M. Featherstone,
"Evaluation of the comprehensiveness, accuracy and currency of the Cochrane COVID-19 Study Register for supporting rapid evidence synthesis production",
Res Synth Methods,
Jun.
2021.
| DOI: | 10.1002/jrsm.1501 |
J. Hildebrandt,
M. I. Metzendorf and
T. Jakob,
"Evaluierung der deutschen Datenbank Current Contents Medizin (CC MED) als potenzielle Datenquelle für das Cochrane COVID-19-Studienregister",
GMS Med Inform Biom Epidemiol,
vol. 17,
no. 3,
pp. Doc12,
2021.
| DOI: | 10.3205/mibe000226 |
| Datei: |
M. Popp,
P. Kranke,
P. Meybohm,
M. Metzendorf,
N. Skoetz,
M. S. Stegemann and
S. Weibel,
"Evidence on the efficacy of ivermectin for COVID-19: another story of apples and oranges",
BMJ Evid Based Med,
vol. 2021,
pp. bmjebm-2021-111791,
2021.
| DOI: | 10.1136/bmjebm-2021-111791 |
J. Wachinger,
M. Schirmer,
N. Täuber and
et al,
"Experiences with opt-in, at-home screening for SARS-CoV-2 at a primary school in Germany: an implementation study",
BMJ Paediatr Open,
vol. 5,
no. 1,
2021.
| DOI: | 10.1136/bmjpo-2021-001262 |
| Datei: | https://doi.org/10.1136/bmjpo-2021-001262 |
[en]
J. M. Tielker,
J. P. Weber,
S. T. Simon,
C. Bausewein,
S. Stiel and
N. Schneider,
"Experiences, challenges and perspectives for ensuring end-of-life patient care: A national online survey with general practitioners in Germany",
PLOS ONE,
vol. 16,
no. 7,
pp. e0254056,
Jul.
2021.
Abstract:
Background The SARS-CoV-2 (COVID-19) pandemic is posing major challenges for health care systems. In Germany, one such challenge has been that adequate palliative care for the severely ill and dying (with and without COVID-19), as well as their loved ones, has not been available at all times and in all settings., the pandemic has underlined the significance of the contribution of general practitioners (GPs) to the care of severely ill and dying patients. Objectives To describe GPs’ experiences, challenges and perspectives with respect to end-of-life care during the first peak of the pandemic (spring 2020) in Germany. Materials and methods In November and December 2020, a link to an Unipark online survey was sent to GPs registered on nationwide distribution lists. Results In total, 410 GPs responded; 61.5% indicated that the quality of their patients’ end-of-life care was maintained throughout the pandemic, 36.8% reported a decrease in quality compared to pre-pandemic times. Of the GPs who made home visits to severely ill and dying patients, 61.4% reported a stable number of visits, 28.5% reported fewer visits. 62.7% of the GPs reported increased telephone contact and reduced personal contact with patients; 36.1% offered video consultations in lieu of face-to-face contact. The GPs reported that relatives were restricted (48.5%) or prohibited from visiting (33.4%) patients in nursing homes. They observed a fear of loneliness among patients in nursing homes (91.9%), private homes (87.3%) and hospitals (86.1%). Conclusions The present work provides insights into the pandemic management of GPs and supports the development of a national strategy for palliative care during a pandemic. To effectively address end-of-life care, GPs and palliative care specialists should be involved in COVID-19 task forces on micro, meso and macro levels of health care.
| DOI: | 10.1371/journal.pone.0254056 |
| Datei: | https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0254056 |
Abstract:
Background The SARS-CoV-2 (COVID-19) pandemic is posing major challenges for health care systems. In Germany, one such challenge has been that adequate palliative care for the severely ill and dying (with and without COVID-19), as well as their loved ones, has not been available at all times and in all settings., the pandemic has underlined the significance of the contribution of general practitioners (GPs) to the care of severely ill and dying patients. Objectives To describe GPs’ experiences, challenges and perspectives with respect to end-of-life care during the first peak of the pandemic (spring 2020) in Germany. Materials and methods In November and December 2020, a link to an Unipark online survey was sent to GPs registered on nationwide distribution lists. Results In total, 410 GPs responded; 61.5% indicated that the quality of their patients’ end-of-life care was maintained throughout the pandemic, 36.8% reported a decrease in quality compared to pre-pandemic times. Of the GPs who made home visits to severely ill and dying patients, 61.4% reported a stable number of visits, 28.5% reported fewer visits. 62.7% of the GPs reported increased telephone contact and reduced personal contact with patients; 36.1% offered video consultations in lieu of face-to-face contact. The GPs reported that relatives were restricted (48.5%) or prohibited from visiting (33.4%) patients in nursing homes. They observed a fear of loneliness among patients in nursing homes (91.9%), private homes (87.3%) and hospitals (86.1%). Conclusions The present work provides insights into the pandemic management of GPs and supports the development of a national strategy for palliative care during a pandemic. To effectively address end-of-life care, GPs and palliative care specialists should be involved in COVID-19 task forces on micro, meso and macro levels of health care.
J. M. Tielker,
J. P. Weber,
S. T. Simon,
C. Bausewein,
S. Stiel and
N. Schneider,
"Experiences, challenges and perspectives for ensuring end-of-life patient care: A national online survey with general practitioners in Germany",
PLoS ONE,
vol. 16,
no. 7,
pp. e0254056,
2021.
| DOI: | 10.1371/journal.pone.0254056 |
M. Muenchhoff,
A. Graf,
S. Krebs and
et al,
"Genomic epidemiology reveals multiple introductions of SARS-CoV-2 followed by community and nosocomial spread, Germany, February to May 2020",
Euro Surveill,
vol. 26,
no. 43,
2021.
| DOI: | 10.2807/1560-7917.ES.2021.26.43.2002066 |
| Datei: | https://doi.org/10.2807/1560-7917.ES.2021.26.43.2002066 |
S. Thun,
J. Sass and
A. Bartschke,
"German Corona Consensus Datensatz (GECCO): Verbesserter Austausch von COVID-19-Forschungsdaten",
kma - Klinik Management aktuell,
vol. 26,
no. 06,
pp. 55—56,
2021.
| DOI: | 10.1055/s-0041-1731187 |
A. Gruber,
T. Firsching,
J. Trimpert and
K. Dietert,
"Hamster models of COVID-19 pneumonia reviewed: How human can they be?",
Vet Pathol,
2021.
M. Schmidt,
S. Kugai and
B. Weltermann,
"Handlungsfähigkeit von Hausärzt*innen während der COVID-19-Pandemie",
DocV-15-05,
2021.
| DOI: | 10.3205/21degam086 |
J. A. F. Klein,
L. J. Krüger,
F. Tobian and
et al,
"Head-to-head performance comparison of self-collected nasal versus professional-collected nasopharyngeal swab for a WHO-listed SARS-CoV-2 antigen-detecting rapid diagnostic test",
Med Microbiol Immunol,
vol. 210,
no. 4,
2021.
| DOI: | 10.1007/s00430-021-00710-9 |
| Datei: | https://doi.org/10.1007/s00430-021-00710-9 |
S. Hadzibegovic,
A. Lena,
T. Churchill,
J. Ho,
S. Potthoff,
C. Denecke,
L. Rösnick,
K. Heim,
M. Kleinschmidt,
L. Sander and
D. Stahl,
"Heart failure with preserved ejection fraction according to the HFA-PEFF score in COVID-19 patients: clinical correlates and echocardiographic findings",
Eur J Heart Fail,
vol. 23,
no. 11,
pp. 1891—1902,
2021.
| DOI: | 10.1002/ejhf.2210 |
R. Groß and
et al,
"Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity against prevalent SARS-CoV-2 variants",
EBioMedicine,
vol. 75,
pp. 103761,
2021.
| DOI: | 10.1016/j.ebiom.2021.103761 |
M. Tenbusch,
S. Schumacher,
E. Vogel and
et al,
"Heterologous prime–boost vaccination with ChAdOx1 nCoV-19 and BNT162b2",
Lancet Infect Dis,
vol. 21,
no. 9,
2021.
| DOI: | 10.1016/S1473-3099(21)00420-5 |
M. Rössler,
J. Jacob,
L. Risch,
F. Tesch,
D. Enders,
D. Wende,
R. Jucknewitz,
O. Weidinger,
M. Batram,
P. Ballesteros,
S. Baßler,
D. Hertle,
U. Repschläger,
N. Richter,
C. Schulte,
A. Schramm,
F. Sobik,
M. Treskova-Schwarzbach,
S. Scholz,
J. Walker and
D. Stahl,
"Hierarchisierung von Risikofaktoren für schwere COVID-19-Erkrankungsverläufe im Kontext der COVID-19-Schutzimpfungen",
2021.
| DOI: | 10.25646/8405.2 |
M. Lehmann,
C. Heldt,
J. Meinhardt,
F. Schmidt and
e. a. Rodriguez-Sillke,
"Human small intestinal infection by SARS-CoV-2 is characterized by a mucosal infiltration with activated CD8(+) T cells",
Mucosal Immunol,
vol. 14,
pp. 1381—1392,
2021.
M. Lehmann,
C. Heldt and
et al,
"Human small intestinal infection by SARS-CoV-2 is characterized by a mucosal infiltration with activated CD8+ T cells",
Mucosal Immunol,
pp. 1-12,
2021.
| DOI: | 10.1038/s41385-021-00437-z |
J. Barros-Martins,
S. I. Hammerschmidt and
A. Cossmann,
"Humoral and cellular immune response against SARS-CoV-2 variants following heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination",
MedRxiv,
2021.
| DOI: | 10.1101/2021.06.01.21258172 |
| Datei: | https://doi.org/10.1101/2021.06.01.21258172 |
S. Trump,
S. Lukassen,
S. M. Anker,
R. L. Chua,
J. Liebig and
e. a. Thurmann,
"Hypertension delays viral clearance and exacerbates airway hyperinflammation in patients with COVID-19",
Nat Biotechnol,
vol. 39,
pp. 705—716,
2021.
| DOI: | 10.1038/s41587-021-00937-2 |
C. Walsh,
P. Tafforeau,
W. Wagner and
et al,
"Imaging intact human organs with local resolution of cellular structures using hierarchical phase-contrast tomography",
Nat Methods,
vol. 18,
no. 12,
pp. 1532-1541,
2021.
| DOI: | 10.1038/s41592-021-01317-x |
J. Barros-Martins and
et al,
"Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination",
Nature Medicine,
vol. 27,
pp. 1525—1529,
2021.
| DOI: | 10.1038/s41591-021-01449-9 |
D. L. Burnett and
et al,
"Immunizations with diverse sarbecovirus receptor-binding domains elicit SARS-CoV-2 neutralizing antibodies against a conserved site of vulnerability",
Immunity,
vol. 54,
pp. 2908—2921.e6,
2021.
| DOI: | 10.1016/j.immuni.2021.10.019 |
E. Schrezenmeier and
et al,
"Immunogenicity of COVID-19 Tozinameran Vaccination in Patients on Chronic Dialysis",
Frontiers in immunology,
vol. 12,
pp. 690698,
2021.
| DOI: | 10.3389/fimmu.2021.690698 |
R. J. Neumann,
B. Kollmann,
J. Brokelmann,
N. M. Werthern,
A. Malsyhau,
D. Weichert,
B. Lutz,
C. J. Fiebach,
M. Wessa and
D. Stahl,
"Impact of COVID-19 lockdown on mental health in Germany: Longitudinal observation of different mental health trajectories and protective factors",
Translational Psychiatry,
vol. 11,
no. 1,
pp. 1—10,
2021.
| DOI: | 10.1038/s41398-021-01508-2 |
B. Mühlemann and
et al,
"Impact of dexamethasone on SARS-CoV-2 concentration kinetics and antibody response in hospitalised COVID-19 patients - results from a prospective observational study",
Clinical microbiology and infection: the official publication of the European Society of Clinical Microbiology and Infectious Diseases,
2021.
| DOI: | 10.1016/j.cmi.2021.06.008 |
B. Mühlemann,
C. Thibeault,
D. Hillus,
E. Helbig,
L. Lippert,
P. Tober-Lau,
T. Schwarz,
M. Müller,
P. group,
M. Witzenrath and
D. Stahl,
"Impact of dexamethasone on SARS-CoV-2 concentration kinetics and antibody response in hospitalized COVID-19 patients: results from a prospective observational study",
Clin Microbiol Infect,
2021.
| DOI: | 10.1016/j.cmi.2021.06.008 |
B. Mühlemann,
C. Thibeault,
D. Hillus,
E. Helbig,
L. Lippert,
P. Tober-Lau,
T. Schwarz,
M. A. Müller,
P. group,
M. Witzenrath,
N. Suttorp,
L. E. Sander,
C. Drosten,
T. C. Jones,
V. M. Corman and
F. Kurth,
"Impact of dexamethasone on SARS-CoV-2 concentration kinetics and antibody response in hospitalized COVID-19 patients: results from a prospective observational study. Clin Microbiol Infect. 2021;27(10)",
2021.
| DOI: | 1520.e7-1520.e10 |
M. Ricke-Hoch,
E. Stelling,
L. Lasswitz,
A. Gunesch,
M. Kasten,
F. Zapatero-Belinchón,
G. Brogden,
G. Gerold,
T. Pietschmann,
V. Montiel,
J. Balligand,
F. Facciotti,
E. Hirsch,
T. Gausepohl,
H. Elbahesh,
G. Rimmelzwaan,
A. Höfer,
M. Kühnel,
D. Jonigk,
J. Eigendorf,
U. Tegtbur,
L. Mink,
M. Scherr,
T. Illig,
A. Schambach,
T. Pfeffer,
A. Hilfiker,
A. Haverich and
D. Hilfiker-Kleiner,
"Impaired immune response mediated by prostaglandin E2 promotes severe COVID-19 disease",
PLoS One,
vol. 16,
no. 8,
pp. e0255335,
Aug.
2021.
| DOI: | 10.1371/journal.pone.0255335 |
N. Dauletbaev,
S. Kuhn,
S. Holtz,
S. Waldmann,
L. Niekrenz,
B. S. Müller,
C. Bellinghausen,
M. Dreher,
G. G. U. Rohde and
C. Vogelmeier,
"Implementation and use of mHealth home telemonitoring in adults with acute COVID-19 infection: A scoping review protocol",
BMJ Open,
vol. 11,
no. 9,
pp. e053819,
2021.
| DOI: | 10.1136/bmjopen-2021-053819 |
A. Müller,
F. S. Melzow,
G. Göstemeyer,
S. Paris and
F. Schwendicke,
"Implementation of COVID-19 Infection Control Measures by German Dentists: A Qualitative Study to Identify Enablers and Barriers",
International Journal of Environmental Research and Public Health,
vol. 18,
no. 11,
pp. 5710,
2021.
| DOI: | 10.3390/ijerph18115710 |
V. Hennig and
et al,
"Increased risk of chronic fatigue and hair loss following COVID-19 in individuals with hypohidrotic ectodermal dysplasia",
Orphanet Journal of Rare Diseases,
vol. 16,
pp. 373,
2021.
| DOI: | 10.1186/s13023-021-02011-z |
J. Weiner,
P. Suwalski,
M. Holtgrewe,
A. Rakitko,
C. Thibeault,
M. Müller,
D. Patriki,
C. Quedenau,
U. Krüger,
V. Ilinsky,
E. Helbig,
L. Lippert,
P. Stubbemann,
X. Wang,
Z. Karadeniz,
J. Saccomanno,
J. Doehn,
R. Hübner,
B. Hinzmann,
S. Siemann,
V. M. Corman,
B. Mühlemann,
C. Drosten,
T. C. Jones,
N. Suttorp,
M. Witzenrath,
S. Hippenstiel,
C. Skurk,
P. Group,
L. E. Sander,
D. Beule,
U. Landmesser,
T. Guettouche,
F. Kurth,
B. Heidecker,
I. Popov,
J. Balnis,
A. Jaitovich,
L. Real,
J. Macías,
J. Pineda,
M. Fernandez-Fuertes,
M. Salvo,
A. Blueher,
S. Jurisic,
J. Beer,
J. Rutishauser,
B. Wiggli,
H. Schmid,
K. Danninger,
R. Binder,
R. Arjun Arkal,
G. Fragiadakis,
E. Mick,
C. Comet,
C. Calfee,
D. Erle,
C. Hendrickson,
K. Kangelaris,
M. Krummel,
P. Woodruff,
C. Langelier,
U. Venkataramani,
F. García,
J. Zyla,
T. Zemojtel,
P. Wolfgang,
T. Borodina and
S. Ripke,
"Increased risk of severe clinical course of COVID-19 in carriers of HLA-C",
04:01. EClinicalMedicine.2021;40:101099,
2021.
J. Weiner,
P. Suwalski,
M. Holtgrewe,
A. Rakitko,
C. Thibeault,
M. Müller,
D. Patriki,
C. Quedenau,
U. Krüger,
V. Ilinsky and
D. Stahl,
"Increased risk of severe clinical course of COVID-19 in carriers of HLA-C*04:01",
EClinicalMedicine,
2021.
| DOI: | 10.1016/j.eclinm.2021.101099 |
S. Dickel,
C. Grimm,
M. Popp,
C. Struwe,
A. Sachkova,
M. Golinski,
C. Seeber,
F. Fichtner,
D. Heise,
P. Kranke,
W. Meissner,
S. Laudi,
S. Voigt-Radloff,
J. Meerpohl,
J. Jabs,
N. Mutters,
O. Moerer and
Group On Behalf Of The German CEOsys Study,
"Infection control, prophylactic antibiotics, and testing for SARS-CoV-2 and PPE on German intensive care units: results from a national mixed methods survey",
GMS Hyg Infect Control,
vol. 16,
pp. Doc21,
2021.
| DOI: | 10.3205/dgkh000392 |
A. M. Köster,
A. Bludau,
S. K. Devcic,
S. Scheithauer,
A. A. Mardiko and
R. Schaumann,
"Infection surveillance measures during the COVID-19 pandemic in Germany",
GMS hygiene and infection control,
vol. 16,
pp. Doc27,
2021.
Abstract:
Introduction: To address the question as to which infection surveillance measures are used during the ongoing COVID-19 pandemic in Germany and how they differ from pre-existing approaches. Methods: In accordance with the systematic approach of a scoping review, a literature search was conducted in national and international medical literature databases using a search string. The search in the databases was limited to the period from 01.01.2000 to 15.11.2020 and has been subsequently completed by hand search until 08.03.2021. A hand search, even beyond 15.11.2020, seemed necessary and reasonable, since due to the dynamics of the ongoing COVID-19 pandemic, a large number of articles and regulations are being published very quickly at short notice. Results: The literature search resulted in the following number of hits in the databases listed below: PubMed: 165 articlesCochrane: 1 review and 35 studiesWeb of Science: 217 articlesRobert Koch Institute: 49 articles Thus, a total of 467 hits were identified, with a total of 124 hits being duplicates. From these, 138 articles were considered relevant to the COVID-19 infection surveillance situation in Germany based on established criteria. After reading the full texts, 92 articles and websites were ultimately included in the scoping review. Discussion: Many of the lessons learned from previous outbreaks seem to have been implemented in the infection surveillance measures during the ongoing COVID-19 pandemic in Germany. Most of the changes compared with previous measures were based on technological streamlining of existing procedures and changes and more inclusion of the population in different infection surveillance measures. Einleitung: Es wird der Frage nachgegangen, welche Maßnahmen zur Infektionsüberwachung während der aktuellen COVID-19-Pandemie in Deutschland eingesetzt werden und wie sie sich von bereits bestehenden Ansätzen unterscheiden.Methoden: Entsprechend der systematischen Vorgehensweise eines Scoping Reviews wird eine Literaturrecherche in nationalen und internationalen medizinischen Literaturdatenbanken mittels Suchstring durchgeführt. Die Suche in den Datenbanken ist auf den Zeitraum vom 01.01.2000 bis zum 15.11.2020 begrenzt und anschließend per Handsuche bis zum 08.03.2021 ergänzt. Eine Handsuche, auch über den 15.11.2020 hinaus, erscheint notwendig und sinnvoll, da aufgrund der Dynamik der laufenden COVID-19-Pandemie sehr kurzfristig eine große Anzahl von Artikeln und Verordnungen veröffentlicht werden.Ergebnisse: Die Literaturrecherche hat die folgende Anzahl von Treffern in den unten aufgeführten Datenbanken ergeben: PubMed: 165 ArtikelCochrane: 1 Review und 35 StudienWeb of Science: 217 ArtikelRobert Koch-Institut: 49 Artikel Somit sind insgesamt 467 Treffer identifiziert worden, wobei insgesamt 124 Treffer Duplikate sind. Anhand festgelegter Kriterien werden 138 Artikel als relevant für die COVID-19-Infektionssurveillance in Deutschland eingestuft, und nach dem Lesen der Volltexte schließlich 92 Artikel und Webseiten in den Scoping Review aufgenommen.Diskussion: Viele der Maßnahmen, die aufgrund früherer Ausbruchsgeschehen bekannt sind, scheinen auch bei der jetzigen Infektionsüberwachung während der laufenden COVID-19-Pandemie in Deutschland umgesetzt worden zu sein. Die meisten Änderungen im Vergleich zu früheren Maßnahmen betreffen technologische Neuerungen sowie eine stärkere Einbeziehung der Bevölkerung in die verschiedenen Maßnahmen zur Infektionsüberwachung.
| DOI: | 10.3205/dgkh000398 |
Abstract:
Introduction: To address the question as to which infection surveillance measures are used during the ongoing COVID-19 pandemic in Germany and how they differ from pre-existing approaches. Methods: In accordance with the systematic approach of a scoping review, a literature search was conducted in national and international medical literature databases using a search string. The search in the databases was limited to the period from 01.01.2000 to 15.11.2020 and has been subsequently completed by hand search until 08.03.2021. A hand search, even beyond 15.11.2020, seemed necessary and reasonable, since due to the dynamics of the ongoing COVID-19 pandemic, a large number of articles and regulations are being published very quickly at short notice. Results: The literature search resulted in the following number of hits in the databases listed below: PubMed: 165 articlesCochrane: 1 review and 35 studiesWeb of Science: 217 articlesRobert Koch Institute: 49 articles Thus, a total of 467 hits were identified, with a total of 124 hits being duplicates. From these, 138 articles were considered relevant to the COVID-19 infection surveillance situation in Germany based on established criteria. After reading the full texts, 92 articles and websites were ultimately included in the scoping review. Discussion: Many of the lessons learned from previous outbreaks seem to have been implemented in the infection surveillance measures during the ongoing COVID-19 pandemic in Germany. Most of the changes compared with previous measures were based on technological streamlining of existing procedures and changes and more inclusion of the population in different infection surveillance measures. Einleitung: Es wird der Frage nachgegangen, welche Maßnahmen zur Infektionsüberwachung während der aktuellen COVID-19-Pandemie in Deutschland eingesetzt werden und wie sie sich von bereits bestehenden Ansätzen unterscheiden.Methoden: Entsprechend der systematischen Vorgehensweise eines Scoping Reviews wird eine Literaturrecherche in nationalen und internationalen medizinischen Literaturdatenbanken mittels Suchstring durchgeführt. Die Suche in den Datenbanken ist auf den Zeitraum vom 01.01.2000 bis zum 15.11.2020 begrenzt und anschließend per Handsuche bis zum 08.03.2021 ergänzt. Eine Handsuche, auch über den 15.11.2020 hinaus, erscheint notwendig und sinnvoll, da aufgrund der Dynamik der laufenden COVID-19-Pandemie sehr kurzfristig eine große Anzahl von Artikeln und Verordnungen veröffentlicht werden.Ergebnisse: Die Literaturrecherche hat die folgende Anzahl von Treffern in den unten aufgeführten Datenbanken ergeben: PubMed: 165 ArtikelCochrane: 1 Review und 35 StudienWeb of Science: 217 ArtikelRobert Koch-Institut: 49 Artikel Somit sind insgesamt 467 Treffer identifiziert worden, wobei insgesamt 124 Treffer Duplikate sind. Anhand festgelegter Kriterien werden 138 Artikel als relevant für die COVID-19-Infektionssurveillance in Deutschland eingestuft, und nach dem Lesen der Volltexte schließlich 92 Artikel und Webseiten in den Scoping Review aufgenommen.Diskussion: Viele der Maßnahmen, die aufgrund früherer Ausbruchsgeschehen bekannt sind, scheinen auch bei der jetzigen Infektionsüberwachung während der laufenden COVID-19-Pandemie in Deutschland umgesetzt worden zu sein. Die meisten Änderungen im Vergleich zu früheren Maßnahmen betreffen technologische Neuerungen sowie eine stärkere Einbeziehung der Bevölkerung in die verschiedenen Maßnahmen zur Infektionsüberwachung.